Exelixis Inc. Common Stock (EXEL)

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOME…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

1,077

Website

www.exelixis.com

Fundamentals

1-day range

$52.17$54.14

Market cap

$13.12B

P/E (trailing)

17.00

P/E (forward)

13.29

EPS (trailing)

$3.18

Dividend yield

—

Beta

0.42

Avg. volume

2.68M

Forecasts

16 analyst ratings

Exelixis Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• EXEL

  Exelixis Inc. Common Stock

  $54.45

  ▼ 1.47%
  Market cap $13.12BP/E 17.00
  $33.76$57.57
• HALO

  Halozyme Therapeutics Inc. Common Stock

  $105.33

  ▼ 1.49%
  Market cap $10.17BP/E 27.63
  $61.23$109.66
• NBIX

  Neurocrine Biosciences Inc. Common Stock

  $153.98

  ▼ 1.24%
  Market cap $16.25BP/E 21.99
  $122.14$186.12
• KYMR

  Kymera Therapeutics Inc. Common Stock

  $118.08

  ▼ 1.79%
  Market cap $8.75BP/E —
  $39.84$130.05
• QGEN

  Qiagen N.V. Common Shares

  $43.12

  ▼ 1.43%
  Market cap $8.60BP/E 22.14
  $32.53$57.82
• TWST

  Twist Bioscience Corporation Common Stock

  $141.16

  ▼ 7.80%
  Market cap $6.84BP/E —
  $23.3$155.44
• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.99BP/E —
  $44.12$78.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Exelixis (EXEL) Q2 2026 Earnings Call Transcript
  Yahoo · 8/13/2026
• Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot
  Yahoo · 8/7/2026
• EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
  Yahoo · 8/6/2026
• Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52
  Benzinga · 8/6/2026
• Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating
  ChartMill · 8/6/2026
• Stifel Maintains Hold on Exelixis, Raises Price Target to $51
  Benzinga · 8/6/2026
• Exelixis, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/6/2026
• Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...
  Yahoo · 8/6/2026

• Sue Gail Eckhardt · June 1, 2026 · Sale

  9.8K @ $50.14
• Jack L. Wyszomierski · June 1, 2026 · Sale

  3.9K @ $50.55
• Sue Gail Eckhardt · May 27, 2026 · Grant

  8.4K
• Tomas J. Heyman · May 27, 2026 · Grant

  8.4K
• Caligan Partners LP · May 27, 2026 · Grant

  19.1K
• Bob Oliver · May 27, 2026 · Grant

  8.4K
• Julie Smith · May 27, 2026 · Grant

  8.4K
• Maria C. Freire · May 27, 2026 · Grant

  8.4K
• Mary C. Beckerle · May 27, 2026 · Grant

  8.4K
• Stelios Papadopoulos · May 27, 2026 · Grant

  8.4K
• George Poste · May 27, 2026 · Grant

  8.4K
• Jack L. Wyszomierski · May 27, 2026 · Grant

  8.4K
• Dana Aftab · May 26, 2026 · Sale

  43.5K @ $50.35
• Patrick J. Haley · May 20, 2026 · Sale

  32.1K @ $49.81
• Brenda Hefti · May 18, 2026 · Sale

  6.6K @ $50.21

Institutional Ownership

March 31, 2026

Total shares held

244.03M

Total value held

$9.88B

Institutional holders

687